Scribe Biosciences
San Francisco
About Scribe Biosciences
Our fundamental technology, Printed Droplet Microfluidics (PDM), is a flexible and reconfigurable fluid handling system to perform picoliter-scale manipulations. By leveraging fluorescence-activated microfluidic droplet sorting and a specialized substrate, PDM enables the flexible and deterministic handling of single cells and fluid aliquots at extremely high throughputs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.1M
- Last round: Non-Equity Assistance (Jun 2023)
- Website: scribebiosciences.com
- Phone: [email protected]
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/scribe-biosciences-134778 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.